REFERENCES
1. Conte M, Petraglia L, Poggio P, et al. Inflammation and cardiovascular diseases in the elderly: the role of epicardial adipose tissue. Front Med. 2022;9:844266.
2. Magnussen C, Alegre-Diaz J, Al-Nasser LA, et al. ; Global Cardiovascular Risk Consortium, The Global Cardiovascular Risk Consortium. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025;393:125-38.
3. Tan SCW, Zheng BB, Tang ML, Chu H, Zhao YT, Weng C. Global burden of cardiovascular diseases and its risk factors, 1990-2021: a systematic analysis for the global burden of disease study 2021. QJM. 2025;118:411-22.
4. Martin SS, Aday AW, Allen NB, et al. ; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151:e41-e660.
5. Lindstrom M, DeCleene N, Dorsey H, et al. Global burden of cardiovascular diseases and risks collaboration, 1990-2021. J Am Coll Cardiol. 2022;80:2372-425.
7. Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71:1857-65.
8. Chin JF, Aga YS, Abou Kamar S, et al. Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity. Eur J Heart Fail. 2023;25:1936-43.
9. Packer M. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Eur Heart J. 2026;47:12-21.
10. Marcelin G, Silveira ALM, Martins LB, Ferreira AV, Clément K. Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis. J Clin Invest. 2019;129:4032-40.
11. Iacobellis G. Epicardial fat links obesity to cardiovascular diseases. Prog Cardiovasc Dis. 2023;78:27-33.
12. Miller RJH, Shanbhag A, Killekar A, et al. AI-derived epicardial fat measurements improve cardiovascular risk prediction from myocardial perfusion imaging. NPJ Digit Med. 2024;7:24.
13. West HW, Siddique M, Williams MC, et al. ; ORFAN Investigators. Deep-learning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction. JACC Cardiovasc Imaging. 2023;16:800-16.
14. Kankaria R, Charla JN, Ye K, et al. Inverse association of insulin-like growth factor binding protein 1 with epicardial and intrathoracic adiposity in older adults: the Longenity study. Diabetes Res Clin Pract. 2026;232:113099.
15. Le Pelletier L, Ngono Ayissi K, Gorwood J, et al. C-C chemokine ligand 5 from women subcutaneous adipose tissue has a central role in vascular aging. Cardiovasc Diabetol. 2025;24:295.
17. Mandl M, Heuboeck E, Benedikt P, et al. The capability to undergo ACSL4-mediated ferroptosis is acquired during brown-like adipogenesis and affected by hypoxia. Cells. 2025;14:1247.
18. Ou MY, Zhang H, Tan PC, Zhou SB, Li QF. Adipose tissue aging: mechanisms and therapeutic implications. Cell Death Dis. 2022;13:300.
19. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593-606.
20. Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2019;16:83-99.
21. Eisenberg E, McElhinney PA, Commandeur F, et al. Deep learning-based quantification of epicardial adipose tissue volume and attenuation predicts major adverse cardiovascular events in asymptomatic subjects. Circ Cardiovasc Imaging. 2020;13:e009829.
22. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404.
23. Calcaterra G, Varghese RT, Baroni M, et al. Earlier prediction of cardiovascular risk with epicardial fat assessment. Eur J Intern Med. 2026;143:106481.
24. Daley AD, Bénézech C. Fat-associated lymphoid clusters: supporting visceral adipose tissue B cell function in immunity and metabolism. Immunol Rev. 2024;324:78-94.
25. Hara T, Sata M. Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications. Cardiovasc Interv Ther. 2025;40:465-73.
26. Rizzuto AS, Gelpi G, Mangini A, Carugo S, Ruscica M, Macchi C. Exploring the role of epicardial adipose-tissue-derived extracellular vesicles in cardiovascular diseases. iScience. 2024;27:109359.
27. Cui L, Yang M. Epicardial adipose tissue: an overtly concealed contributor to cardiovascular events in chronic kidney disease patients. Lipids Health Dis. 2025;25:16.
28. Tian Y, Wang P, Dong Z. Heart-guarding or heart-harming? The dual role of epicardial adipose tissue in cardiovascular health and disease. Int J Obes. 2025;49:2156-67.
29. Janssen-Telders C, Eringa EC, de Groot JR, de Man FS, Handoko ML. The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovasc Res. 2025;121:860-70.
30. Shah RV, Anderson A, Ding J, et al. Pericardial, but not hepatic, fat by CT is associated with cv outcomes and structure: the multi-ethnic study of atherosclerosis. JACC Cardiovasc Imaging. 2017;10:1016-27.
31. Kenchaiah S, Ding J, Carr JJ, et al. Pericardial fat and the risk of heart failure. J Am Coll Cardiol. 2021;77:2638-52.
32. Shahrori Z, Chedid El Helou M, Sallam S, Iacobellis G, Neeland IJ. The role of pericardial fat in cardiometabolic disease: emerging evidence and therapeutic potential. Curr Cardiol Rep. 2025;27:141.
33. Shia YX, Pappritz K, Kaltenbach AC, et al. Pericardial adipose tissue promotes transition to heart failure with reduced ejection fraction upon pressure-overload in mice. Basic Res Cardiol. 2025;120:925-45.
34. Polkinghorne MD, West HW, Antoniades C. Adipose tissue in cardiovascular disease: from basic science to clinical translation. Annu Rev Physiol. 2024;86:175-98.
35. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450-7.
36. Vincenzi M, Nebigil CG. Uncovering the role of prokineticin pathway on epicardial adipose tissue (EAT) development and EAT-associated cardiomyopathy. Trends Cardiovasc Med. 2025;35:328-38.
37. Heuboeck E, Bhogal CS, Mandl M. Heart matters: how glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning. Diabetes Obes Metab. 2026;28:878-94.
38. Santos D, Burgeiro A, Fonseca ACRG, et al. Assessing the interaction of the UCP system and fatty acids on epicardial adipose tissue mitochondrial respiration. Eur J Clin Invest. 2026;56:e70149.
39. Bauzá-Thorbrügge M, Vujičić M, Chanclón B, et al. Adiponectin stimulates Sca1+CD34--adipocyte precursor cells associated with hyperplastic expansion and beiging of brown and white adipose tissue. Metabolism. 2024;151:155716.
40. Doukbi E, Soghomonian A, Sengenès C, et al. Browning epicardial adipose tissue: friend or foe? Cells. 2022;11:991.
41. Ghesmati Z, Rashid M, Fayezi S, Gieseler F, Alizadeh E, Darabi M. An update on the secretory functions of brown, white, and beige adipose tissue: towards therapeutic applications. Rev Endocr Metab Disord. 2024;25:279-308.
42. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118:1786-807.
43. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci. 2021;135:731-52.
44. Chen H, Liu L, Li M, Zhu D, Tian G. Epicardial adipose tissue-derived leptin promotes myocardial injury in metabolic syndrome rats through PKC/NADPH oxidase/ROS pathway. J Am Heart Assoc. 2023;12:e029415.
45. McCauley MD, Iacobellis G, Li N, Nattel S, Goldberger JJ. Targeting the substrate for atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2024;83:2015-27.
46. Packer M. Epicardial Adipose Tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71:2360-72.
47. Kandi SR, Khera R, Rajagopalan S, Neeland IJ. AI in adipose imaging: revolutionizing visceral adipose tissue, ectopic fat, and cardiovascular risk assessment. Curr Atheroscler Rep. 2025;27:101.
48. Wang Q, Li H, Huan Y, et al. Adipose tissue: an inflammatory organ that can not be ignored in periodontal disease related to obesity. Front Immunol. 2025;16:1698207.
49. Mohaghegh N, Balajam NZ, Hosseinpour B, et al. Immunoengineering strategies using nanoparticles for obesity treatment. Nano Res. 2025;18:94907707.
50. Patel KHK, Hwang T, Se Liebers C, Ng FS. Epicardial adipose tissue as a mediator of cardiac arrhythmias. Am J Physiol Heart Circ Physiol. 2022;322:H129-44.
51. Karakasis P, Stachteas P, Iliakis P, et al. Inflammation and resolution in obesity-related cardiovascular disease. Int J Mol Sci. 2026;27:535.
52. Zou R, Zhang M, Lv W, Ren J, Fan X. Role of epicardial adipose tissue in cardiac remodeling. Diabetes Res Clin Pract. 2024;217:111878.
53. Queiroz M, Sena CM. Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health. Cardiovasc Diabetol. 2024;23:455.
54. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460-6.
55. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-84.
56. Thomas D, Apovian C. Macrophage functions in lean and obese adipose tissue. Metabolism. 2017;72:120-43.
57. Kratz M, Coats BR, Hisert KB, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014;20:614-25.
58. Boutens L, Hooiveld GJ, Dhingra S, Cramer RA, Netea MG, Stienstra R. Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses. Diabetologia. 2018;61:942-53.
59. Muñoz Sarmiento DM, Ferreira Cortés DY, Caicedo Pérez M, et al. Finite element analysis predicts a major mechanical role of epicardial adipose tissue in atherosclerotic coronary disease and angioplasty. Comput Methods Programs Biomed. 2025;262:108656.
60. Gao Z, Zuo Y, Jia L, et al. Correlation analysis between epicardial adipose tissue and acute coronary syndrome. Sci Rep. 2025;15:3015.
61. Sárvári AK, Doan-Xuan QM, Bacsó Z, Csomós I, Balajthy Z, Fésüs L. Interaction of differentiated human adipocytes with macrophages leads to trogocytosis and selective IL-6 secretion. Cell Death Dis. 2015;6:e1613.
62. Omoto ACM, Vechetti I, do Carmo JM, et al. Leptin activates brain-BAT-heart crosstalk to promote cardiac protection. Circ Res. 2026;138:e326878.
63. Vyas V, Hunter RJ, Longhi MP, Finlay MC. Inflammation and adiposity: new frontiers in atrial fibrillation. Europace. 2020;22:1609-18.
64. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22:1311-9.
65. Guglielmo M, Lin A, Dey D, et al. Epicardial fat and coronary artery disease: role of cardiac imaging. Atherosclerosis. 2021;321:30-8.
66. Nogajski Ł, Mazuruk M, Kacperska M, et al. Epicardial fat density obtained with computed tomography imaging - more important than volume? Cardiovasc Diabetol. 2024;23:389.
67. Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017;38:1294-302.
68. Friedrich MG. The future of cardiovascular magnetic resonance imaging. Eur Heart J. 2017;38:1698-701.
69. Nappi C, Ponsiglione A, Vallone C, et al. Association of cardiovascular risk factors and coronary calcium burden with epicardial adipose tissue volume obtained from PET-CT imaging in oncological patients. J Cardiovasc Dev Dis. 2024;11:331.
70. Kitagawa T, Nakamoto Y, Fujii Y, et al. Relationship between coronary arterial 18F-sodium fluoride uptake and epicardial adipose tissue analyzed using computed tomography. Eur J Nucl Med Mol Imaging. 2020;47:1746-56.
71. Kwiecinski J, Dey D, Cadet S, et al. Peri-coronary adipose tissue density is associated with 18F-sodium fluoride coronary uptake in stable patients with high-risk plaques. JACC Cardiovasc Imaging. 2019;12:2000-10.
72. Antonopoulos AS, Sanna F, Sabharwal N, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017;9:eaal2658.
73. Chan K, Wahome E, Tsiachristas A, et al. ; ORFAN Consortium. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. Lancet. 2024;403:2606-18.
74. Oikonomou EK, Marwan M, Desai MY, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet. 2018;392:929-39.
75. Commandeur F, Goeller M, Razipour A, et al. Fully automated CT quantification of epicardial adipose tissue by deep learning: a multicenter study. Radiol Artif Intell. 2019;1:e190045.
76. Li X, Wang Z, Wang S, et al. Combining computed tomography features of left atrial epicardial and pericoronary adipose tissue with the triglyceride-glucose index to predict the recurrence of atrial fibrillation after radiofrequency catheter ablation: a machine learning study. Quant Imaging Med Surg. 2024;14:9306-22.
77. Lee J, Hu T, Williams MC, et al. Detection of arterial remodeling using epicardial adipose tissue assessment from CT calcium scoring scan. Front Cardiovasc Med. 2025;12:1543816.
78. Lee J, Hu T, Williams MC, et al. Prediction of obstructive coronary artery disease using coronary calcification and epicardial adipose tissue assessments from CT calcium scoring scans. J Cardiovasc Comput Tomogr. 2025;19:224-31.
79. Singh P, Hoori A, Freeze J, et al. Leveraging calcium score CT radiomics for heart failure risk prediction. Sci Rep. 2024;14:26898.
80. Berman DS, Lin A. Artificial intelligence for assessment of epicardial adipose tissue on coronary CT angiography. JACC Cardiovasc Imaging. 2023;16:817-9.
81. Song YJ, Zhao XY, Wang LJ, et al. Epicardial adipose tissue and heterogeneity parameters combined with inflammatory cells to predict the value of heart failure with preserved ejection fraction patients post myocardial infarction. Cardiovasc Diabetol. 2025;24:192.
82. Gaibazzi N, Martini C, Benatti G, Palumbo AA, Cacciola G, Tuttolomondo D. Atrial fibrillation and peri-atrial inflammation measured through adipose tissue attenuation on cardiac computed tomography. Diagnostics. 2021;11:2087.
83. El Mahdiui M, Simon J, Smit JM, et al. Posterior left atrial adipose tissue attenuation assessed by computed tomography and recurrence of atrial fibrillation after catheter ablation. Circ Arrhythm Electrophysiol. 2021;14:e009135.
84. Beyer C, Tokarska L, Stühlinger M, et al. Structural cardiac remodeling in atrial fibrillation. JACC Cardiovasc Imaging. 2021;14:2199-208.
85. Tzoulaki I, Castagné R, Boulangé CL, et al. Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur Heart J. 2019;40:2883-96.
86. Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. Am J Epidemiol. 2014;180:129-39.
87. Neeland IJ, Zhu F, Graca G, et al. Metabolomics profiling of epicardial adipose tissue: MESA and the rotterdam study. J Am Heart Assoc. 2025;14:e039750.
88. Riecan M, Kasperova BJ, Vondrackova M, et al. Epicardial adipose tissue produces L-3-hydroxybutyrate in advanced heart failure: direct analysis of fat metabolic remodeling. Metabolism. 2026;175:156465.
89. Scherer M, Montoliu I, Qanadli SD, et al. Blood plasma lipidomic signature of epicardial fat in healthy obese women. Obesity. 2015;23:130-7.
90. Barchuk M, Dutour A, Ancel P, et al. Untargeted lipidomics reveals a specific enrichment in plasmalogens in epicardial adipose tissue and a specific signature in coronary artery disease. Arterioscler Thromb Vasc Biol. 2020;40:986-1000.
91. Barchuk M, Ancel P, Miksztowicz V, et al. Epicardial adipose tissue ceramides are related to lipoprotein lipase activity in coronary artery disease: unfolding a missing link. Arterioscler Thromb Vasc Biol. 2022;42:e242-51.
92. Schoepf UJ, Abadia AF. Greasing the skids: deep learning for fully automated quantification of epicardial fat. Radiol Artif Intell. 2019;1:e190140.
93. Xiao H, Wang X, Yang P, Wang L, Xi J, Xu J. Impact of CT reconstruction algorithms on pericoronary and epicardial adipose tissue attenuation. Eur J Radiol. 2025;188:112132.
94. Vianello E, Dozio E, Bandera F, et al. Dysfunctional EAT thickness may promote maladaptive heart remodeling in CVD patients through the ST2-IL33 system, directly related to EPAC protein expression. Sci Rep. 2019;9:10331.
95. Huang K, Lu J, Li Q, et al. The role of epicardial adipose tissue-derived proteins in heart failure with preserved ejection fraction and atrial fibrillation: a bioinformatics analysis. J Inflamm Res. 2024;17:6093-111.
96. Kuneman JH, van Rosendael SE, van der Bijl P, et al. Pericoronary adipose tissue attenuation in patients with acute coronary syndrome versus stable coronary artery disease. Circ Cardiovasc Imaging. 2023;16:e014672.
97. Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011;58:248-55.
98. Overgaard KS, Andersen TR, Heinsen LJ, et al. Pericoronary adipose tissue attenuation predicts compositional plaque changes: a 12-month longitudinal study in individuals with type 2 diabetes without symptoms or known coronary artery disease. Cardiovasc Diabetol. 2025;24:143.
99. Mohamed W, Ishak KN, Baharum N, et al. Ethnic disparities and its association between epicardial adipose tissue thickness and cardiometabolic parameters. Adipocyte. 2024;13:2314032.
100. Wu YW, Chang TT, Chang CC, Chen JW. Fatty-acid-binding protein 4 as a novel contributor to mononuclear cell activation and endothelial cell dysfunction in atherosclerosis. Int J Mol Sci. 2020;21:9245.
101. Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation. 2003;108:472-8.
102. Szydełko J, Zapolski T, Lenart-Lipińska M, et al. Epicardial adipose tissue mediates the association between circulating hsa-miR-4750-3p and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2026;25:39.
103. Ocana G, Michaud K, Magnin V, et al. Coronary CT angiography-derived pericoronary fat attenuation index: post-mortem histopathological correlation in fatal plaques. Int J Cardiol. 2025;435:133388.
104. Ke Y, Cao Z, Wang X, et al. KCa3.1 promotes the migration of macrophages from epicardial adipose tissue to induce vulnerability to atrial fibrillation during rapid pacing. Can J Cardiol. 2025;41:195-209.
105. Chen Y, Fang C, Liu W, et al. Dysregulation of adipocytokines via the hsa-miR-548ay-3p/PPARγ signaling pathway leads to cardiac fibrosis. Sci Rep. 2025;15:11324.
106. Shaihov-Teper O, Ram E, Ballan N, et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation. Circulation. 2021;143:2475-93.
107. Fan Y, Huang S, Li S, et al. The adipose-neural axis is involved in epicardial adipose tissue-related cardiac arrhythmias. Cell Rep Med. 2024;5:101559.
108. Nalliah CJ, Bell JR, Raaijmakers AJA, et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality. J Am Coll Cardiol. 2020;76:1197-211.
109. Cui H, Shu S, Zhang N, et al. Plasma CCL3 predicts adverse heart failure outcomes in patients with arrhythmogenic cardiomyopathy. BMC Med. 2025;23:213.
110. Lapolla D, Canovi L, Berloni ML, et al. Epicardial adipose tissue in arrhythmogenic cardiomyopathy. Biology. 2025;14:278.
111. Mahmoud B, Cox MGPJ, de Brouwer R, et al. Epicardial adipose tissue and malignant ventricular arrhythmias in phospholamban p.(Arg14del) variant carriers. Eur Heart J. 2025;46:1766-8.
112. Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23:1858-71.
113. Menghoum N, Badii MC, Leroy M, et al. Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2025;24:134.
114. Jin X, Hung CL, Tay WT, et al. Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. Eur J Heart Fail. 2022;24:1346-56.
115. Rossi VA, Nebunu D, Haider T, et al. Diverging role of epicardial adipose tissue across the entire heart failure spectrum. ESC Heart Fail. 2023;10:3419-29.
116. Doesch C, Haghi D, Flüchter S, et al. Epicardial adipose tissue in patients with heart failure. J Cardiovasc Magn Reson. 2010;12:40.
117. Yang CD, Quan JW, Tay GP, et al. Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction. Cardiovasc Diabetol. 2024;23:283.
118. Khidr SS, Bakeer BM, Helmy HA, El-Naggar HM. Cardiac magnetic resonance quantified epicardial fat volume is associated with complex coronary artery disease among diabetics. Cardiovasc Diabetol. 2025;24:64.
119. Akoumianakis I, Sanna F, Margaritis M, et al. Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases. Sci Transl Med. 2019;11:eaav5055.
120. Araki M, Sugiyama T, Nakajima A, et al. Level of vascular inflammation is higher in acute coronary syndromes compared with chronic coronary disease. Circ Cardiovasc Imaging. 2022;15:e014191.
121. Wang J, Wang J, Zhong J, et al. LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization. Proc Natl Acad Sci U S A. 2024;121:e2405845121.
122. Sreejit G, Abdel-Latif A, Athmanathan B, et al. Neutrophil-derived S100A8/A9 amplify granulopoiesis after myocardial infarction. Circulation. 2020;141:1080-94.
123. Liu Z, Liu J, Wang X, et al. Nε-carboxyethyl-lysin influences atherosclerotic plaque stability through ZKSCAN3 acetylation-regulated macrophage autophagy via the RAGE/LKB1/AMPK1/SIRT1 pathway. Cardiovasc Diabetol. 2025;24:36.
124. Filtz A, Lorenzatti D, Scotti A, et al. Epicardial adipose tissue, coronary plaque progression, and major adverse cardiovascular events: a multicenter study. JACC Cardiovasc Imaging. 2026;19:720-31.
125. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-66.
126. Nakajima A, Sugiyama T, Araki M, et al. Plaque rupture, compared with plaque erosion, is associated with a higher level of pancoronary inflammation. JACC Cardiovasc Imaging. 2022;15:828-39.
127. Pieszko K, Shanbhag A, Killekar A, et al. Deep learning of coronary calcium scores from PET/CT attenuation maps accurately predicts adverse cardiovascular events. JACC Cardiovasc Imaging. 2023;16:675-87.
128. Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-42.
129. Cosson E, Nguyen MT, Rezgani I, et al. Epicardial adipose tissue volume and coronary calcification among people living with diabetes: a cross-sectional study. Cardiovasc Diabetol. 2021;20:35.
130. de Vos AM, Prokop M, Roos CJ, et al. Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J. 2008;29:777-83.
131. Molnar D, Björnson E, Hjelmgren O, Adiels M, Bäckhed F, Bergström G. Coronary artery calcifications are not associated with epicardial adipose tissue volume and attenuation on computed tomography in 1,945 individuals with various degrees of glucose disorders. Int J Cardiol Heart Vasc. 2025;56:101613.
132. Mancio J, Azevedo D, Saraiva F, et al. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2018;19:490-7.
133. Zobel EH, Christensen RH, Winther SA, et al. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. Cardiovasc Diabetol. 2020;19:16.
134. Suffee N, Moore-Morris T, Jagla B, et al. Reactivation of the epicardium at the origin of myocardial fibro-fatty infiltration during the atrial cardiomyopathy. Circ Res. 2020;126:1330-42.
135. Haemers P, Hamdi H, Guedj K, et al. Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria. Eur Heart J. 2017;38:53-61.
136. Sun W, Wu Y, Gao M, et al. C-reactive protein promotes inflammation through TLR4/NF-κB/TGF-β pathway in HL-1 cells. Biosci Rep. 2019;39:BSR20190888.
137. Feng L, Li L, Bai L, Tang L, Zhao Y, Zhao X. The association between features of epicardial adipose tissue and the risks of early recurrence after catheter ablation in patients with atrial fibrillation. Front Cardiovasc Med. 2025;12:1480473.
138. Chamoun N, Chahine Y, Kassar A, et al. Reduction in left atrial epicardial adipose tissue following catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2025;18:e013590.
139. Sommariva E, Brambilla S, Carbucicchio C, et al. Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy. Eur Heart J. 2016;37:1835-46.
140. Heidenreich PA, Bozkurt B, Aguilar D, et al. ; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
141. Solomon SD, Ostrominski JW, Wang X, et al. ; STEP-HFpEF Trial Committees and Investigators. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024;84:1587-602.
142. Kramer CM, Borlaug BA, Zile MR, et al. ; SUMMIT Trial Study Group. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85:699-706.
143. Dronkers J, van Veldhuisen DJ, van der Meer P, Meems LMG. Heart failure and obesity: unraveling molecular mechanisms of excess adipose tissue. J Am Coll Cardiol. 2024;84:1666-77.
144. Capone F, Sotomayor-Flores C, Bode D, et al. Cardiac metabolism in HFpEF: from fuel to signalling. Cardiovasc Res. 2023;118:3556-75.
145. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6-19.
146. Yu WJ, Jiang WX, Liu SJ, Li HH, Lin QY. Single-cell RNA sequencing reveals that myeloid S100A8/A9 is a novel regulator of the transition from adaptive hypertrophy to heart failure after pressure overload. Theranostics. 2025;15:8587-608.
147. Yang W, Wu Z, Yang K, et al. BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway. Am J Physiol Heart Circ Physiol. 2019;316:H61-9.
148. Paterek A, Załęska-Kocięcka M, Wojdyńska Z, et al. Epicardial fat in heart failure-Friend, foe, or bystander. Obes Rev. 2024;25:e13820.
149. Liu J, Yu Q, Li Z, et al. Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study. Cardiovasc Diabetol. 2023;22:45.
150. Frisk C, Ekström M, Eriksson MJ, et al. Characteristics of gene expression in epicardial adipose tissue and subcutaneous adipose tissue in patients at risk for heart failure undergoing coronary artery bypass grafting. BMC Genomics. 2024;25:938.
151. Komici K, Bencivenga L, Arganese C, Rengo G, Guerra G. The relationship between muscle strength and epicardial fat in healthy adults. Exp Gerontol. 2024;192:112447.
152. Yu L, Wan Q, Liu Q, et al. IgG is an aging factor that drives adipose tissue fibrosis and metabolic decline. Cell Metab. 2024;36:793-807.e5.
153. Camell CD, Günther P, Lee A, et al. Aging induces an Nlrp3 inflammasome-dependent expansion of adipose B cells that impairs metabolic homeostasis. Cell Metab. 2019;30:1024-1039.e6.
154. Camell CD, Sander J, Spadaro O, et al. Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing. Nature. 2017;550:119-23.
155. Liu WB, Wang SS, Zhang X, et al. Enhanced cardiomyocyte NLRP3 inflammasome-mediated pyroptosis promotes d-galactose-induced cardiac aging. J Am Heart Assoc. 2024;13:e032904.
156. Rämö JT, Kany S, Hou CR, et al.; FinnGen. Cardiovascular significance and genetics of epicardial and pericardial adiposity. JAMA Cardiol. 2024;9:418-27.
157. Myasoedova VA, Parisi V, Moschetta D, et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22:23.
158. Christensen RH, Wedell-Neergaard AS, Lehrskov LL, et al. Effect of aerobic and resistance exercise on cardiac adipose tissues: secondary analyses from a randomized clinical trial. JAMA Cardiol. 2019;4:778-87.
159. Christensen RH, Lehrskov LL, Wedell-Neergaard AS, et al. Aerobic exercise induces cardiac fat loss and alters cardiac muscle mass through an interleukin-6 receptor-dependent mechanism: cardiac analysis of a double-blind randomized controlled clinical trial in abdominally obese humans. Circulation. 2019;140:1684-6.
160. Launbo N, Zobel EH, von Scholten BJ, Faerch K, Jørgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: a systematic review and meta-analysis. Obes Rev. 2021;22:e13136.
161. Alexopoulos N, Melek BH, Arepalli CD, et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol. 2013;61:1956-61.
162. Raggi P, Gadiyaram V, Zhang C, Chen Z, Lopaschuk G, Stillman AE. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering: a potential pleiotropic effect. J Am Heart Assoc. 2019;8:e013104.
163. Iacobellis G. Epicardial fat inflammation and GLP-1/GIP receptor analogs: are we shifting our perspective? Curr Cardiol Rep. 2025;27:161.
164. Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity. 2017;25:311-6.
165. Kosiborod MN, Petrie MC, Borlaug BA, et al. ; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394-407.
166. Manubolu VS, Lakshmanan S, Kinninger A, et al. Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (semaglutide treatment effect on coronary atherosclerosis progression) randomized trial. J Am Coll Cardiol. 2024;84:865-7.
167. Packer M, Zile MR, Kramer CM, et al. ; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427-37.
168. Díaz-Rodríguez E, Agra RM, Fernández AL, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018;114:336-46.
169. Takano M, Kondo H, Harada T, et al. Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile. JACC Basic Transl Sci. 2023;8:1081-97.
170. Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: a systematic review and network meta-analysis. Diabetes Obes Metab. 2025;27:1096-112.
171. Cinti F, Leccisotti L, Sorice GP, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349.
172. Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32.
173. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K. Surgical obesity treatment and the risk of heart failure. Eur Heart J. 2019;40:2131-8.
174. Gaborit B, Jacquier A, Kober F, et al. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol. 2012;60:1381-9.
175. van Woerden G, van Veldhuisen SL, Rienstra M. Incident heart failure risk after bariatric surgery: the role of epicardial fat. Eur Heart J. 2020;41:1775.
176. Sorimachi H, Obokata M, Omote K, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol. 2022;80:1501-12.
177. Lecoutre S, Rebière C, Maqdasy S, et al. Enhancing adipose tissue plasticity: progenitor cell roles in metabolic health. Nat Rev Endocrinol. 2025;21:272-88.
178. Avtanski D, Hadzi-Petrushev N, Josifovska S, Mladenov M, Reddy V. Emerging technologies in adipose tissue research. Adipocyte. 2023;12:2248673.
